| |
Ceptaris Therapeutics Inc. is
developing a proprietary gel formulation of mechlorethamine
hydrochloride (mechlorethamine) for the treatment of early stage
(stages I-IIA) mycosis fungoides, a type of CTCL. Based upon
results of a pivotal trial, Ceptaris submitted a new drug
application (NDA) with the Food and Drug Administration (FDA) in
2011. If approved, Ceptaris’ investigational drug would be the
first topical mechlorethamine product available to
treat the signs and symptoms of this rare cancer.
learn more
|
|
|
|
